<DOC>
	<DOCNO>NCT02369731</DOCNO>
	<brief_summary>This study perform post-approval safety study ( PASS ) , per Pharmacovigilance Risk Assessment Committee ( PRAC ) European Medicines Agency ( EMA ) , gather data Translarna ( ataluren ) safety , effectiveness , prescription pattern routine clinical practice .</brief_summary>
	<brief_title>Registry Translarna ( Ataluren ) Nonsense Mutation Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>This multicenter , observational study patient receive Translarna base inclusion data registry . This study intend enroll 200 patient across ~50 care center Europe region period ~ 2 year . The study population include patient receive usual care treatment commercial supply Translarna ( receive care within name patient early access program ) provide consent . Patients follow least 5 year date enrollment . Safety efficacy data collect conjunction routine visit conduct per usual care . Although protocol-mandated procedure , expect physician caregiver follow publish treatment guideline standard care .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Receiving receive usual care treatment commercial supply Translarna ( receive care within name patient early access program ) Willing provide write informed consent allow study data collection procedure ( either patient authorisation legal guardian ) Patients receive ataluren placebo blind , randomize clinical trial , ataluren ataluren clinical trial cohort early access program prevents participation study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>